New Eanm Award Supports Alpha Radioligand Therapy Research

Applications are now unfastened for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), intends to accelerate innovative investigation successful alpha radioligand therapy (α-RLT) successful prostate cancer. Winners will beryllium recognized crossed 3 grant categories: Platinum (40,000 euros), Gold (20,000 euros), and Silver (10,000 euros) awards. 

Alpha radioligand therapy is quickly emerging arsenic a transformative frontier successful precision oncology, and we powerfully judge successful nan talent of researchers astatine nan opening of their careers successful this field. This grant was designed to nurture their maturation by pairing investigation excellence pinch system training, mentorship, and collaborative networking opportunities." 

Paola Anna Erba, EANM President 

Shaping nan early of prostate cancer  

EANM invites applications from early profession researchers - PhD candidates, postdoctoral fellows, inferior faculty, and clinicians-in-training - who are wrong 10 years of their terminal grade and affiliated pinch an institution successful an EANM personnel country. 

Applicants must submit a project proposal aimed astatine offering clinically meaningful advances to prostate crab curen pinch nan usage of α-RLT. Priority areas include optimising clinical use, tailoring the treatment to individual patients, and identifying patients who might benefit the astir from it. The deadline for exertion is May 18, 2026, at 23:59 CEST via [email protected].